References
- Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in an Italian tamoxifen chemoprevention trial. Br Med J 2005; 330: 932
- Bauditz J, Schmidt HH, Dippe P, Lochs H, Pirlich M. Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid. Am J Gastroenterol 2004; 99: 959–60
- Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739–43
- Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 2003; 98: 2348–50
- Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734–8
- Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462–8
- Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31
- Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002; 2: 11–9
- Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, the LIDO Study Group, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898–906